Baltic Countries

ScanBalt celebrates its 10th anniversary


Under the motto “10 Years ScanBalt Bioregion – Towards a Balanced Regional Development and Smart Specialisation in the Baltic Sea Region”, the ScanBalt Bio­Region is holding the 10th ScanBalt Forum from September 21st-23rd. Launched in 2001, ScanBalt has become the most significant cooperation network for the life sciences and health sector in Northern Europe. The cross-border initiative that is headquartered in Copenhagen encompasses a region of 85 million inhabitants, 60 universities, 248 hospitals and about 2,500 life science and biotech com­panies – around 700 of which are SMEs.

The key issue for ScanBalt is to bundle the interests of its 67 members in the Baltic Sea Region, as well as North-West Russia, Norway and the Northern Netherlands. And the network is accomplishing that task with increasing success. So far, 15 international projects for companies, universities, and research facilities have been initiated and supported under the ScanBalt umbrella, all of them aimed at developing the areas bordering the Baltic Sea into a globally competitive meta-region. Taking yearly turns, members rotate duties in the ScanBalt Forum in order to strengthen cross-border cooperation within the ScanBalt Bio region. Following the founding session at the first Baltic Biotech Forum, which took place in Teschow in the German State of Mecklenburg-Vorpommern in 2001, the event has migrated almost completely around the Baltic Sea region from Oslo to Tallinn. The meeting in Heringsdorf on the German/Polish island of Usedom marks the return of ScanBalt to the southernmost areas of the initiative.

Flagship for Europe:

the Baltic Sea Health Region

The agenda of this year’s Forum is filled with topics like the EU flagship “Baltic Sea Health Region” project, the “Green Valley”project with environmental projects and activities in the region, and the opportunities and challenges of cross-border cooperation in the Baltic Sea Region. Contributors to the 2010 ScanBalt Forum in Tallin (Estonia) successfully managed to incorporate the “ScanBalt Health Region” project as a keystone in the EU Baltic Sea Strategy, and added proposals to the emerging 8th EU Research Framework Programme, which includes a “Master Plan on Health“ for the Baltic Sea region.
Successes like these have encouraged the 2011 Forum organisers. ScanBalt chairman Wolfgang Blank has high expectations: “The ScanBalt BioRegion has emerged as a model region for Europe in the cooperation between business, universities, and the public sector. In future, we need to keep working to improve the mobility of people, know­ledge, and ideas within Europe, and to reduce regional inequalities. In Heringsdorf, we are attempting to pave the way for well-balanced regional development.”

Cross-border success

Lectures and workshops are one way to present new projects from areas that include ­regenerative medicine, marine and industrial biotechnology, the fight against multi-resistant bacteria, identifying and defining new areas of cooperation, developing expansion strategies in the life sciences and health economy fields, and for mobilising resources for implementation. 250 participants from business, science, and the public sector are expected at the Forum, which falls under the patronage of Mecklenburg-Vorpommern, currently led by state premiere Erwin Sellering. Anyone interested is welcome to attend (registration at:
The ScanBalt Forum is organised by the West Pomeranian Medical University Szczecin/Poland, the University of Klaipeda/Lithuania and as part of the project Eco4­Life, which is partly financed by the EU (European Regional Development Fund). The lead partner is BioCon Valley® GmbH, a central contact and service provider for life sciences, biotechnology and the bio­sciences in Mecklenburg-Vorpommern.

Politics / Law


The human race is at war with another species, and has been for thousands of years. Each of us in Europe swats dead dozens of the enemy every summer, and in the tropics they kill thousands of people with infectious diseases...

Tech Review


The Philogen group is a specialist for therapies against cancer. Unlike other private companies, the Swiss-Italian firm has developed a rich pipeline of antibodies consisting of five different molecules being tested in 15...

Tech Review


Success in the biopharmaceutical industry is mainly driven by the ability to innovate, and the continuous development of new products is crucial in that context. Shortening development times is key. The use of comprehensive...

Tech Review


Zurich-based NeurImmune AG follows unconventional routes – for example, the company doesn’t rely on VC investors. And Neurimmune has also turned the drug discovery process upside down by taking its drug candidates from healthy...

Tech Review


The use of bispecific antibodies recognising two different targets may allow improvement of clinical efficacy. A bispecific antibody for two growth factors that stimulate the formation of blood vessels – Ang2 (Angiopoietin-2) and...

Clinical Trial


Sweden’s Karo Bio AB has been hit hard by toxicity issues with its lead compound eprotirome. The anti-cholesterol drug – which was in Phase III clinical development – proved unsafe in a long-term animal tests. The drug lead to...

Clinical Trial


Inspiration Biopharmaceuticals Inc. reported on 22 February that its lead candidate drug proved successful in a clinical trial involving 12 patients who suffer from hemophilia B. The results were presented at the 5th Annual EAHAD...

Displaying results 21 to 30 out of 1983

< Previous 21-30 Next >

© 2007-2016 BIOCOM


Current issue

All issues

Product of the week


Stock list

All quotes


  • MOLMED (I)0.42 EUR7.69%


  • PHOTOCURE (N)46.40 NOK-8.12%
  • VERNALIS (UK)43.00 GBP-4.44%
  • E-THERAPEUTICS (UK)11.75 GBP-4.08%


  • DIAMYD MEDICAL -B- (S)7.05 SEK64.0%
  • KARO BIO (S)38.30 SEK28.5%
  • VALNEVA (F)2.89 EUR26.2%


  • BIONOR PHARMA (N)0.47 NOK-23.0%
  • NOVOZYMES (DK)284.10 DKK-14.1%
  • RENEURON (UK)2.75 GBP-12.7%


  • KARO BIO (S)38.30 SEK2387.0%
  • NICOX (F)10.33 EUR455.4%
  • SAREUM HOLDINGS (UK)0.74 GBP252.4%


  • BB BIOTECH (D)46.45 EUR-81.8%
  • EVOCUTIS (UK)0.04 GBP-78.9%
  • NOVACYT (F)1.30 EUR-71.7%

No liability assumed, Date: 24.08.2016


All Events